

# Proton Pump Inhibitor Use Is Not Strongly Associated With A Nationwide Study and Meta-analysis

Clinical Gastroenterology and Hepatology  
19, 1845-1854.e6

DOI: 10.1016/j.cgh.2021.05.011

Citation Report

#	ARTICLE	IF	CITATIONS
1	COVID-19 mortality- The culprit may not be proton pump inhibitors. Clinical Gastroenterology and Hepatology, 2021, , .	4.4	0
3	Proton Pump Inhibitor Use: A Risk Factor for Inflammatory Bowel Disease or an Innocent Bystander?. Gastroenterology, 2021, 161, 1789-1791.	1.3	4
4	Eosinophilic Esophagitis Patients Are Not At Increased Risk of Severe COVID-19: A Report from a Global Registry. Journal of Allergy and Clinical Immunology: in Practice, 2021, , .	3.8	6
5	Proton-pump inhibitor use is not associated with severe COVID-19-related outcomes: a propensity score-weighted analysis of a national veteran cohort. Gut, 2022, 71, 1447-1450.	12.1	3
6	The Association Between Proton Pump Inhibitors and COVID-19 is Confounded by Hyperglycemia in a Population-Based Study. Frontiers in Pharmacology, 2022, 13, 791074.	3.5	3
7	The Use of Proton Pump Inhibitors and COVID-19: A Systematic Review and Meta-Analysis. Tropical Medicine and Infectious Disease, 2022, 7, 37.	2.3	13
8	Impact of Coronavirus Disease 2019 on the Pediatric Population with Aerodigestive Disease. Journal of Pediatrics, 2022, 243, 14-20.e1.	1.8	1
10	Using anti-acid therapy in era of COVID-19 pandemic: Potential pros and cons. Medical Alphabet, 2022, , 38-40.	0.2	0
11	Proton Pump Inhibitors in the COVID-19 Pandemic. Russian Archives of Internal Medicine, 2022, 12, 245-253.	0.2	0
13	Factors Associated With Poor Outcomes Among Patients With SARS-CoV-2 Coronavirus Infection and Gastrointestinal Symptoms. , 2023, 2, 37-45.		2
14	What is the role of proton pump inhibitors consumption on the clinical presentation and severity of COVID-19 infection?. Annales Pharmaceutiques Francaises, 2022, , .	1.0	0
15	The impact of COVID-19 infection on miscellaneous inflammatory disorders of the gastrointestinal tract.. Gastroenterology Clinics of North America, 2022, , .	2.2	1
16	People exposed to protonâ€pump inhibitors shortly preceding COVIDâ€19 diagnosis are not at an increased risk of subsequent hospitalizations and mortality: A nationwide matched cohort study. British Journal of Clinical Pharmacology, 0, , .	2.4	1
17	The elusive role of proton pump inhibitors in COVID-19: Can plasma Chromogranin A levels hold the key?. Pharmacological Research, 2023, 187, 106601.	7.1	0
18	Histamine-2 Receptor Antagonists and Proton Pump Inhibitors Are Associated With Reduced Risk of SARS-CoV-2 Infection Without Comorbidities Including Diabetes, Hypertension, and Dyslipidemia: A Propensity Score-Matched Nationwide Cohort Study. Journal of Korean Medical Science, 2023, 38, .	2.5	0
19	Antacids in real clinical practice. Meditsinskiy Sovet, 2023, , 59-67.	0.5	0
20	How to Make the Right Choice of Proton Pump Inhibitor for Patients with Gastroesophageal Reflux Disease?. Russian Journal of Gastroenterology Hepatology Coloproctology, 2023, 33, 68-76.	1.1	0
21	The impact of <scp>COVID</scp>â€19 on Japanese patients with eosinophilic gastrointestinal disorders during the vaccination era. JGH Open, 2023, 7, 702-707.	1.6	0

#	ARTICLE	IF	CITATIONS
22	COVID-19 and Gastrointestinal Tract: From Pathophysiology to Clinical Manifestations. Medicina (Lithuania), 2023, 59, 1709.	2.0	0